RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to realise investments and the loss of the value of investment. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme.
Please read FULL risk warning.
Ambicare Health Ltd has developed a portfolio of wearable light sources for medical and consumer healthcare applications.
Investment closes only once the total pledged amount passes the minimum of £400,000
A pledge is not a commitment. You will be asked to confirm in the next section.
This company has not shared it's twitter feed.
olds. There are a number of therapeutic and over the counter (OTC) treatments available however many of the therapies fail to deliver effective treatment or manage the symptoms of acne. There is also a growing concern about chemicals used in certain treatments and the dangerous side effects this can cause. For this reason, acne sufferers are beginning to turn to phototherapy devices. Ambicare Health has identified the issues caused by the current devices and has introduced the first hands free blue light emitting device, allowing users complete freedom to do other things whilst undergoing treatment to heal and eliminate acne.
Ambicare Health is a company that has spun out of the University of St. Andrews and the Ninewells Hospital and Medical School in 2004. Ambicare has made significant progress in the development and commercialisation of the wearable and light emitting diode (LED) based devices with a range of medical and consumer healthcare applications. Whilst using blue light therapy to treat acne is not a new concept, Ambicare have been the first to introduce handsfree devices that can be used at home or away from home called Lustre Pure Light. The technology to make Lustre derived from Ambicare’s first product, Ambulight PDT, which was used to successfully cure forms of skin cancer. While the Lustre product range has gained significant interest and highly satisfied its users, Ambicare identified that its existing products are expensive to manufacture and thus expensive to sell. This has resulted in Ambicare releasing a new product in the Lustre product range, Lustre Solo.
Ambicare has a revenue generating product portfolio, with key sales channels through Boots and Amazon.
Investment Focus: Equity and Debt
About: Envestors is a FCA regulated corporate finance adviser in the UK and operates an international network of sophisticated investors investing an average of £42,000 in high growth unquoted companies seeking £250,000 to £2m in equity funding.
Contact Name: Oliver Woolley
Registered InvestorsOver 1000
Investment through platformOver £100m